DBV Technologies S.A. — Investor Relations & Filings

DBV Technologies is a clinical-stage company focused on developing treatments for food allergies. Its core technology is the proprietary Viaskin patch, an investigational platform for epicutaneous immunotherapy (EPIT). This technology is designed to administer allergens to intact skin, aiming to re-educate the immune system and induce tolerance without significant transfer of the antigen into the bloodstream. The company's lead product candidate, Viaskin Peanut (DBV712), is in late-stage clinical development for the treatment of peanut allergy. The development pipeline also includes Viaskin Milk (DBV135) for milk allergies, which has completed early-stage clinical studies.